Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
571 studies found for:    Open Studies | "Hormones"
Show Display Options
Rank Status Study
21 Recruiting Safety and Efficacy Phase 2 Study of Long-acting hGH (MOD-4023) in Growth Hormone Deficient Children
Condition: Pediatric Growth Hormone Deficiency
Interventions: Drug: MOD-4023;   Drug: Somatropin
22 Recruiting A Phase 3, Multicenter Study Designed To Evaluate The Efficacy And Safety Of A Long Acting Hgh Product (Mod-4023) In Adult Subjects With Growth Hormone Deficiency
Condition: Adult Growth Hormone Deficiency
Interventions: Drug: MOD-4023;   Other: Placebo
23 Not yet recruiting Bone Structure in Patients With Adult Onset Growth Hormone Deficiency Assessed Using High Resolution Peripheral Quantitative Computed Tomography
Condition: Adult Onset Growth Hormone Deficiency
Intervention:
24 Recruiting CO11109: A Phase 1b Study of TAK-700 in Postmenopausal Women With Hormone-receptor Positive Metastatic Breast Cancer
Condition: Post Menopausal, Hormone Receptor Positive Breast Cancer
Intervention: Drug: TAK700
25 Recruiting A PK Study of 3 Dosages of Tolvaptan in Patients With Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH)
Condition: Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH)
Intervention: Drug: tolvaptan
26 Recruiting DETECT IV - A Multicenter Single Arm Phase II Study to Investigate Clinical Efficacy of Everolimus in Combination With Endocrine Therapy in Postmenopausal Patients With Hormone-receptor+ve, HER2-ve MBC and Persisting HER2-ve CTCs
Conditions: HER2-negative Und Hormone-receptor Positive Metastatic Breast Cancer;   HER2-negative Circulating Tumor Cells;   Postmenopausal Female Patients
Intervention: Drug: Everolimus in combination with standard endocrine therapy
27 Recruiting Versartis Long-Term Extension Study of VRS-317
Condition: Pediatric Growth Hormone Deficiency
Intervention: Drug: VRS-317
28 Recruiting Safety Study of Adding Everolimus to Adjuvant Hormone Therapy in Women With Poor Prognosis, ER+ and HER2- Primary Breast Cancer, Free of Disease After Receiving 3 Years of Adjuvant Hormone Therapy
Conditions: Primary Non-metastatic Breast Cancer;   Who Remain Disease-free After Receiving at Least 1 Year of Adjuvant Hormone Therapy
Interventions: Drug: Everolimus;   Drug: Placebo
29 Recruiting Pegvisomant With Glucagon Test to Assess for Adult Growth Hormone Deficiency
Condition: Adults Growth Hormone Deficiency.
Interventions: Drug: Pegvisomant;   Drug: Regular insulin
30 Not yet recruiting The Effect of Medical Clown on the Pain and Anxiety Perception During LRH Analog Treatment or GH Provocation Test
Conditions: Precocious Puberty;   Growth Hormone Tests
Intervention: Behavioral: Presence of medical clown during endocrine test
31 Recruiting Patient Preference for Everolimus in Combination With Exemestane or Capecitabine in Combination With Bevacizumab
Conditions: Breast Cancer Recurrent;   HER2/Neu-negative Carcinoma of Breast;   Hormone Receptor Positive Malignant Neoplasm of Breast
Interventions: Drug: Bevacizumab;   Drug: Capecitabine;   Drug: Everolimus;   Drug: Exemestane;   Other: Patient questionaires
32 Recruiting Analysis of Tumor Tissue and Circulating Genetic Material in the Blood to Obtain Further Insight in the Effectiveness of Everolimus When Combined With Exemestane
Conditions: Hormone Receptor Positive Malignant Neoplasm of Breast;   Metastatic Breast Cancer
Intervention: Drug: Everolimus plus Exemestane
33 Recruiting Interdisciplinary Pituitary Disorders Centre of Excellence: Assessment of Patient Education Tools
Conditions: Pituitary Neoplasms;   Prolactinoma;   ACTH-Secreting Pituitary Adenoma;   Gigantism;   Growth Hormone-Secreting Pituitary Adenoma
Intervention: Other: Educational Intervention
34 Recruiting Abiraterone Acetate in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
Conditions: Adenocarcinoma of the Prostate;   Hormone-resistant Prostate Cancer;   Recurrent Prostate Cancer;   Stage IV Prostate Cancer
Interventions: Drug: abiraterone acetate;   Drug: prednisone;   Other: laboratory biomarker analysis;   Other: pharmacological study
35 Recruiting Cabozantinib-S-Malate in Treating Patients With Hormone-Resistant Metastatic Prostate Cancer
Conditions: Adenocarcinoma of the Prostate;   Hormone-resistant Prostate Cancer;   Recurrent Prostate Cancer;   Stage IV Prostate Cancer
Interventions: Drug: cabozantinib-s-malate;   Radiation: fluorine F 18 d-FMAU;   Procedure: positron emission tomography;   Other: pharmacological study;   Other: laboratory biomarker analysis
36 Recruiting Enzalutamide and Mifepristone in Treating Patients With Metastatic Hormone Resistant Prostate Cancer
Conditions: Hormone-resistant Prostate Cancer;   Recurrent Prostate Cancer;   Stage IV Prostate Cancer
Interventions: Drug: enzalutamide;   Drug: mifepristone;   Other: laboratory biomarker analysis;   Other: pharmacological study
37 Recruiting Alisertib, Abiraterone Acetate and Prednisone in Treating Patients With Hormone-Resistant Prostate Cancer
Conditions: Adenocarcinoma of the Prostate;   Hormone-resistant Prostate Cancer;   Recurrent Prostate Cancer;   Stage IV Prostate Cancer
Interventions: Drug: Alisertib;   Drug: Abiraterone acetate;   Drug: Prednisone
38 Recruiting CYT107 With or Without Vaccine Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
Conditions: Hormone-resistant Prostate Cancer;   Recurrent Prostate Cancer;   Stage IV Prostate Cancer
Interventions: Biological: glycosylated recombinant human interleukin-7;   Other: laboratory biomarker analysis
39 Recruiting Docetaxel, Prednisone, and Pasireotide in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
Conditions: Adenocarcinoma of the Prostate;   Hormone-resistant Prostate Cancer;   Recurrent Prostate Cancer;   Stage IV Prostate Cancer
Interventions: Drug: docetaxel;   Drug: pasireotide;   Drug: prednisone
40 Recruiting Radiation Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Receiving Sipuleucel-T
Conditions: Bone Metastases;   Hormone-resistant Prostate Cancer;   Recurrent Prostate Cancer;   Stage IV Prostate Cancer
Interventions: Radiation: radiation therapy;   Other: laboratory biomarker analysis

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years